Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

UBYLEE HEALTHCARE GROUP, PLLC

NPI: 1265942403 · MATTHEWS, NC 28105 · Family Medicine Physician · NPI assigned 10/02/2017

$1.08M
Total Medicaid Paid
35,350
Total Claims
27,937
Beneficiaries
14
Codes Billed
2020-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialMARINO, BAPTISTE (MEDICAL DIRECTOR/OWNER)
NPI Enumeration Date10/02/2017

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 1,882 $70K
2021 3,213 $105K
2022 7,007 $141K
2023 10,358 $302K
2024 12,890 $463K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 14,252 10,502 $613K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 2,367 1,962 $188K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3,593 3,135 $180K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 650 595 $39K
96127 6,195 5,094 $17K
96160 6,186 5,091 $15K
80305 1,351 955 $10K
99205 Prolong outpt/office vis 116 101 $8K
20553 256 169 $6K
90791 Psychiatric diagnostic evaluation 24 22 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 269 252 $1K
99442 37 21 $649.90
J1885 Injection, ketorolac tromethamine, per 15 mg 27 24 $18.23
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 27 14 $0.00